Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

Phase 1 Completed 13 enrolled Kyowa Kirin, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis.

Timeline

Start: 2014-05
Primary completion: 2014-12
Completion: 2014-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EVOCALCET	Small molecule	—	Oral

Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

Summary

Timeline

Drugs

Indications